Presence
Podcasts, interviews, and media appearances.
Jefferies London Healthcare Conference 2025
Meeting the Moment in Biopharma Transactions: A Conversation With Leading Executives and Investors Steering Companies Through Uncertainty
Panelist at the Jefferies London Healthcare Conference 2025, joining leading executives and investors in a conversation on navigating biopharma transactions through uncertainty — covering deal strategy, market timing, and the evolving dynamics shaping healthcare M&A and investment.
Speaking·
Key takeaways
BIO 2025
The Future of RNA Therapeutics
Invited speaker at BIO 2025, presenting on the future of RNA therapeutics for Samyang — covering the scientific and investment landscape for next-generation RNA medicines.
Speaking·
IDC Network Annual Meeting 2025
The State of AI in Life Sciences and Healthcare
Invited speaker at the IDC Network Annual Meeting, an exclusive gathering of the IDC multi-fund platform's investors and portfolio leaders spanning private equity, venture capital, real estate, energy, and impact investing.
Speaking·
BIOS
Ventures #24 — Jeffrey Low, MD
Jeffrey Low, MD joins the BIOS Ventures podcast as Principal at Novo Holdings Growth Investments, discussing his path from a16z to Novo, his investment focus at the intersection of life sciences and technology, and how he thinks about backing companies across therapeutics and healthcare.
Podcast·
Harvard Business School
Hone Your Health Care VC Investment Thesis
Alumni panelist at Harvard Business School's healthcare VC investment thesis workshop, a small-group discussion with healthcare investors including Steve Kraus (Bessemer), Evan Caplan (OrbiMed), Ian Chiang (Flare Capital), Ann DeWitt (The Engine), and others.
Speaking·
Cambridge Innovation Institute
Emerging Trends, Evolving Landscapes, & Effective Collaboration
Panelist at the Cambridge Innovation Institute's AI Innovation Circle, discussing emerging trends at the intersection of AI and life sciences, evolving investment landscapes, and effective collaboration between technology and biopharma.
Speaking·
MedCity News
Investment Trends in Precision Medicine
Jeffrey Low, MD, then Principal at Novo Growth, joined a panel on investment trends in precision medicine with Peter Micca (Deloitte), Julie Grant (Canaan), and Christopher McFadden (KKR Credit). Covered by MedCity News.
Speaking·
Read recap
Forbes
Forbes 30 Under 30 in Venture Capital
Named to the Forbes 30 Under 30 list in Venture Capital, recognizing emerging leaders shaping the future of investing across technology, healthcare, and the life sciences.
Feature·
View profile
a16z Podcast
Shifting Risk Mindsets, From Tech to Bio
A conversation exploring the mindset shifts required when building biotechnology companies — from different paths to market and pharma partnerships to different timelines and milestones that distinguish bio ventures from traditional tech startups. With Vijay Pande and Jorge Conde.
Podcast·
Read recap
a16z Podcast
Consolidation in Healthcare: What to Make of It?
A conversation on the wave of consolidation sweeping healthcare — from the CVS-Aetna merger to Amazon's entry — and what it means for startups, patients, and the future of care delivery.
Podcast·
a16z Podcast
Taking the Pulse on Bio
Jeffrey Low, MD interviews the a16z bio team — Jorge Conde, Vijay Pande, and Malinka Walaliyadde — on where biology is becoming more like engineering, the trends shaping the new Century of Biology, and the announcement of a16z's second bio fund.
Podcast·
a16z Summit 2017
Scaling Healthcare
Jeffrey Low, MD moderated a panel at the 2017 a16z Summit with Sean Duffy, CEO of Omada Health, and Raj Singh, CEO of Accolade, on how digital health companies innovate within healthcare's constraints to drive change — covering go-to-market strategies, pricing, and measuring savings. Later published as an a16z podcast episode.
Speaking·
Read recapHarvard Business School
The Future of Healthcare Investment
Moderator at Harvard Business School on the future of healthcare investment, alongside Steve Kraus (Bessemer Venture Partners), Jon Lim (F-Prime Capital), Robbie Greenglass (Waterline Ventures), Charles Huang (Lynchpin Technologies), and Meridith Unger (Nix).
Speaking·